ONCIMMUNE HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.5 GBX | -1.21% |
|
-7.20% | -2.78% |
| Feb. 29 | EARNINGS: Leeds awaiting Hemmers sale, Macfarlane ups full-year payout | AN |
| Feb. 29 | Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Oncimmune Holdings plc is a United Kingdom-based immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiaries include Oncimmune Americas LLC, Oncimmune Germany GmbH, and Oncimmune LLC, among others.
Sector
Pharmaceuticals
Calendar
2024-10-30
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.78% | 22.86M | |
| +5.73% | 71.48B | |
| +11.73% | 9.18B | |
| -15.34% | 4.79B | |
| +34.54% | 3.98B | |
| +5.09% | 3.97B | |
| +27.76% | 2.56B | |
| -28.33% | 2.29B | |
| -24.15% | 2.23B | |
| +6.23% | 1.92B |
- Stock Market
- Equities
- ONC Stock
- News Oncimmune Holdings plc
- Oncimmune : Lung Test Shows Mortality Benefit in Follow-Up Data From Trial
